Tokorozawa City, Japan
Tokorozawa, Saitama
Recruiting
Surgery Plus Chemo Versus Chemoradiotherapy Followed by Surgery Plus Chemo for Locally Recurrent Rectal Cancer
In all, 110 patients from 43 Japanese institutions will be recruited over a period of 6 years. Eligible patients would be registered and randomly assigned to each group with an allocation ratio of 1:1. The primary endpoint is local relapse-free survival. The secondary endpoints are overall survival, relapse-free survival, proportion of local relapse, proportion of distant relapse, proportion of patients with pathological R0 resection, response rate of preoperative chemoradiotherapy (preoperative chemoradiotherapy arm), pathological complete response rate (preoperative chemoradiotherapy arm), proportion of patients who completed the protocol treatment, incidence of adverse events (adverse reactions), and quality of life after surgery.
Phase
3Span
474 weeksSponsor
National Cancer Center Hospital EastTokorozawa
Recruiting
A Study to Evaluate SAR441566 Efficacy and Safety in Adults With Rheumatoid Arthritis
The overall study duration for each participant will be approximately up to 149 days.
Phase
2Span
92 weeksSponsor
SanofiTokorozawa
Recruiting
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
Phase
3Span
1302 weeksSponsor
Merck Sharp & Dohme LLCTokorozawa, Saitama
Recruiting